Creator: Patrick Connole

News Now|Operations|Compliance|Regulatory

Weed: What to Know After Feds Ease Restrictions

Freestyle2 min readMay 6, 2026
Article thumbnail

Now that the feds have rescheduled certain marijuana-related products, long-term care providers may need to adjust their own policies in accordance with this easing of restrictions.

Now that the feds have rescheduled certain marijuana-related products from Schedule I to Schedule III, long-term care providers may need to adjust their own policies in accordance with what amounts to a significant easing of restrictions.


In a new blog post, Amy Miller, director of clinical and regulatory services, American Health Care Association, said the change applies mainly to FDA-approved marijuana-based medications and marijuana products used under state medical cannabis programs.


“These products are now recognized as having medical use and a lower risk level than before,” Miller said.


The result for long-term care providers could be a change in the handling of these medications. She said the areas to focus on are:


  • Prescribing: Providers may see increased use of cannabis-based medications, like Marinol (currently Schedule III), Syndros/dronabinol, and Epidiolex (hemp-derived), prescribed by practitioners. “However, for state-approved cannabis products, obtaining these products follows state-specific rules,” Miller said.


  • Compliance: These products will still be regulated, making it necessary for facilities to follow rules similar to other controlled medications.


  • Documentation and Storage: Proper recordkeeping, storage, and security requirements will apply.


Miller said state medical marijuana programs remain important, and if the state in which a provider operates allows medical cannabis, “those rules still guide how products are used in your facility.”


For now, she said providers should review medication policies and procedures. In addition, facilities should talk with their pharmacy and medical director, train staff on handling controlled substances, and stay updated on federal and state requirements.


“This change does not fully legalize marijuana, but it may increase access to certain cannabis-based medications. Providers should be prepared to manage these products safely and in compliance with laws and regulations,” Miller said.


Comments or questions? Contact Patrick Connole at pconnole@parkplacelive.com.

Previous article
News Now|Clinical|Operations|Regulatory
CMS Takes Further Whack at Prior Authorizations

CMS Takes Further Whack at Prior Authorizations

Patrick ConnoleMay 7, 2026
Next article
News Now|Reimbursement|Compliance|Regulatory
Keep Vigilant for SNF QRP/VBP Data Validation Program Audits

Keep Vigilant for SNF QRP/VBP Data Validation Program Audits

Patrick ConnoleMay 6, 2026
Weed: What to Know After Feds Ease Restrictions - News Now | Park Place